PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22481098-5	2012	The maximum dose of epoprostenol given was 55.3+-10.7 ng kg(-1) min(-1) (range, 21.0-110.5 ng kg(-1) min(-1)).	Epoprostenol	20-32	CD59 molecule (CD59 blood group)	Homo sapiens	64-70	
24084219-9	2014	When SQ treprostinil was converted to IV epoprostenol, the dose decreased from 24.5 (17.5-30) to 13.3 (9-20) ng kg-1 min-1.	Epoprostenol	41-53	CD59 molecule (CD59 blood group)	Homo sapiens	117-122	
22481098-5	2012	The maximum dose of epoprostenol given was 55.3+-10.7 ng kg(-1) min(-1) (range, 21.0-110.5 ng kg(-1) min(-1)).	Epoprostenol	20-32	CD59 molecule (CD59 blood group)	Homo sapiens	101-107	
16391888-5	2007	Dyspnea, Raynaud"s phenomenon, and pulmonary hypertension improved with low-dose epoprostenol (3.0 to 4.0 ng kg(-1) min(-1)).	Epoprostenol	81-93	CD59 molecule (CD59 blood group)	Homo sapiens	116-122	
16391888-8	2007	It appears that pulmonary hypertension can be controlled with low-dose epoprostenol such as 3.0 to 4.0 ng kg(-1) min(-1) in some rheumatic patients.	Epoprostenol	71-83	CD59 molecule (CD59 blood group)	Homo sapiens	113-119	
8473524-5	1993	Kinetic analysis revealed the PGI2 synthetic rate to be 14 ng/min-1 per million cells and t1/2 of PGI2 synthesis, 13.3 min.	Epoprostenol	30-34	CD59 molecule (CD59 blood group)	Homo sapiens	62-67	
10464856-4	1999	Aerosolized epoprostenol, equivalent to the maximum tolerated intravenous dose (31.2 micrograms), produced a 58% fall in pulmonary vascular resistance, increased the cardiac output by 42% and improved functional performance by one MET (3.5 ml kg-1 min-1 of oxygen uptake) without any significant side-effects.	Epoprostenol	12-24	CD59 molecule (CD59 blood group)	Homo sapiens	248-253	
9458458-4	1997	Prostacyclin was nebulized with 81.min-1 of oxygen and administered in doses increasing from 15 to 50 ng.kg-1.min-1 via a facemask.	Epoprostenol	0-12	CD59 molecule (CD59 blood group)	Homo sapiens	35-40	
9458458-4	1997	Prostacyclin was nebulized with 81.min-1 of oxygen and administered in doses increasing from 15 to 50 ng.kg-1.min-1 via a facemask.	Epoprostenol	0-12	CD59 molecule (CD59 blood group)	Homo sapiens	110-115	
9458458-5	1997	Eight of these patients also received intravenous prostacyclin in doses of 1 to 5 ng.kg-1.min-1 and nitric oxide in doses of 10 to 100 ppm via a facemask.	Epoprostenol	50-62	CD59 molecule (CD59 blood group)	Homo sapiens	90-95	
7977706-4	1994	The rate constant of PGI2 synthesis from PGH2 was 0.13 min-1.	Epoprostenol	21-25	CD59 molecule (CD59 blood group)	Homo sapiens	55-60	
3912001-2	1985	During graded intravenous administration of PGI2, platelet aggregation was inhibited at a minimum dose of 4 ng kg-1 min-1.	Epoprostenol	44-48	CD59 molecule (CD59 blood group)	Homo sapiens	116-121	
3325091-7	1987	Epoprostenol was administered at a fixed dose of 5 mg kg-1 min-1 for 0.5-24 h daily for 3-7 days.	Epoprostenol	0-12	CD59 molecule (CD59 blood group)	Homo sapiens	59-64	
3311362-3	1987	Stimulated prostacyclin production was not reduced by storage of vein for 2 h at 23 degrees C in blood or saline nor by distension, but it was reduced to 5.0(0.6) pg.min-1 per mg (n = 10) by de-endothelialisation.	Epoprostenol	11-23	CD59 molecule (CD59 blood group)	Homo sapiens	166-171	
3912001-4	1985	Diastolic BP was significantly reduced and PRA was increased by PGI2 at a dose greater than 8 ng kg-1 min-1.	Epoprostenol	64-68	CD59 molecule (CD59 blood group)	Homo sapiens	102-107	
6362696-1	1983	Epoprostenol (prostacyclin, PGI2) was given intravenously to seven healthy volunteers in a dose of 4 ng kg-1 min-1 over a 30 min period.	Epoprostenol	0-12	CD59 molecule (CD59 blood group)	Homo sapiens	109-114	
6197766-2	1983	20 patients received a constant dose of 8 ng kg-1 min-1 of prostacyclin (PGI2), beginning two minutes before extracorporeal circulation (ECC) and ending together with ECC.	Epoprostenol	59-71	CD59 molecule (CD59 blood group)	Homo sapiens	50-55	
6105392-1	1980	When prostacyclin (5 ng kg-1 min-1) was given during dialysis it enhanced the biological activity of heparin and prevented the activation and consumption of platelets.	Epoprostenol	5-17	CD59 molecule (CD59 blood group)	Homo sapiens	29-34